Quick Takeaways
- PMVP - PMV Pharmaceuticals, Inc. has 17 insiders with reported activity on this page.
- Net insider value flow over the last year: -$2,572,104.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 17 Insiders of PMV Pharmaceuticals, Inc.
- Symbol
- PMVP on Nasdaq
- Location
- Princeton, NJ
What Changed
- Buy value: ; sell value: $2,572,104.
- Net share flow: -1,642,876.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$2,572,104.
Buys
$0
Shares: 0
Insiders: 0
Sells
$2,572,104
Shares: 1,642,876
Insiders: 5
Net
-$2,572,104
Shares: -1,642,876
Insiders: -5
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 1,000,000 | $0 | $1,520,000 | -$1,520,000 |
| 6-9 | 0 | 500,000 | $0 | $900,000 | -$900,000 |
| 9-12 | 0 | 142,876 | $0 | $152,104 | -$152,104 |
PMV Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| INTERWEST PARTNERS X LP | 10%+ Owner | $10,040,531 | Mixed | 13 Jul 2021 | ||
| ORBIMED ADVISORS LLC | 10%+ Owner | $7,562,442 | -$2,420,000 | -24% | Filing P/S | 23 Oct 2025 |
| Thilo Schroeder | Director | $2,455,861 | Mixed | 06 Oct 2021 | ||
| David Henry Mack | President and CEO, Director | $697,788 | -$62,179 | -8.2% | Mixed | 05 Mar 2026 |
| Euclidean Capital LLC | 10%+ Owner | $283,431 | Mixed | 11 Jun 2021 | ||
| Robert Ticktin | General Counsel & COO | $105,090 | -$24,651 | -19% | Filing P/S | 05 Mar 2026 |
| Leila Alland | Chief Medical Officer | $102,377 | Mixed | 15 Sep 2023 | ||
| Deepika Jalota | Chief Development Officer | $95,761 | -$35,198 | -27% | Filing P/S | 05 Mar 2026 |
| Michael Carulli | Chief Financial Officer | $92,310 | -$30,077 | -25% | Median | 05 Mar 2026 |
| Winston Kung | Coo, Cfo | Mixed | 12 May 2023 | |||
| Laurie Stelzer | Director | Mixed | 05 Jun 2025 | |||
| Arnold J. Levine | Director | Mixed | 05 Jun 2025 | |||
| Carol Giltner Gallagher | Director | Mixed | 05 Jun 2025 | |||
| Richard A. Heyman | Director | Mixed | 05 Jun 2025 | |||
| Charles M. Baum | Director | Mixed | 05 Jun 2025 | |||
| Peter A. Thompson | Director, 10%+ Owner | Mixed | 02 Jun 2021 | |||
| Kirsten Flowers | Director | Mixed | 05 Jun 2025 |
Top shareholders of PMV Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| INTERWEST PARTNERS X LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,502,480
|
$10,040,531 | — | 13 Jul 2021 | |
| ORBIMED ADVISORS LLC |
3/4/5
13F
|
10%+ Owner · Company |
9.4%
|
4,975,291
|
$7,562,442 | -$2,420,000 | 23 Oct 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Company |
8.9%
|
4,720,357
|
$6,702,907 | $0 | 16 Sep 2025 | |
| BML Capital Management, LLC |
13F
|
Company |
10%
|
5,292,000
|
$6,615,000 | — | 31 Dec 2025 | |
| BML Investment Partners, L.P. |
13D/G
|
— |
9.9%
|
5,292,000
|
$6,615,000 | +$2,527,616 | 31 Dec 2025 | |
| ArrowMark Colorado Holdings LLC |
13D/G
13F
|
Company |
5.8%
|
3,090,093
|
$3,862,616 | $0 | 31 Dec 2025 | |
| Sio Capital Management, LLC |
13D/G
13F
|
Company |
5%
|
2,636,548
|
$3,691,167 | -$1,538,387 | 30 Sep 2025 | |
| Euclidean Capital LLC |
13F
3/4/5
|
Company · 10%+ Owner |
4.9%
|
2,627,643
|
$3,284,554 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.1%
|
2,170,310
|
$2,712,888 | — | 31 Dec 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
3.8%
|
2,015,770
|
$2,518,000 | — | 31 Dec 2025 | |
| Thilo Schroeder |
3/4/5
|
Director |
—
class O/S missing
|
1,101,283
|
$2,455,861 | — | 06 Oct 2021 | |
| Stonepine Capital Management, LLC |
13F
|
Company |
2.2%
|
1,150,759
|
$1,438,449 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
2.1%
|
1,094,883
|
$1,368,605 | — | 31 Dec 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.6%
|
874,100
|
$1,092,625 | — | 31 Dec 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.3%
|
706,061
|
$882,576 | — | 31 Dec 2025 | |
| David Henry Mack |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
1,253,047
mixed-class rows
|
$697,788 | -$62,179 | 05 Mar 2026 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.99%
|
524,350
|
$655,438 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.94%
|
498,641
|
$623,301 | — | 31 Dec 2025 | |
| Aldebaran Capital, LLC |
13F
|
Company |
0.9%
|
477,988
|
$597,485 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.87%
|
465,086
|
$581,358 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.84%
|
446,140
|
$557,802 | — | 31 Dec 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.81%
|
428,853
|
$536,066 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.72%
|
382,088
|
$477,611 | — | 31 Dec 2025 | |
| Walleye Capital LLC |
13F
|
Company |
0.63%
|
335,694
|
$419,618 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.45%
|
240,138
|
$300,173 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.34%
|
183,178
|
$228,973 | — | 31 Dec 2025 | |
| RBF Capital, LLC |
13F
|
Company |
0.3%
|
162,200
|
$202,750 | — | 31 Dec 2025 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.26%
|
140,468
|
$175,585 | — | 31 Dec 2025 | |
| EVOKE WEALTH, LLC |
13F
|
Company |
0.25%
|
133,122
|
$166,403 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.24%
|
127,041
|
$158,801 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.22%
|
118,593
|
$148,241 | — | 31 Dec 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.2%
|
104,485
|
$130,606 | — | 31 Dec 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.19%
|
101,008
|
$126,260 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.19%
|
98,875
|
$123,595 | — | 31 Dec 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.17%
|
89,136
|
$111,421 | — | 31 Dec 2025 | |
| Robert Ticktin |
3/4/5
|
General Counsel & COO |
—
mixed-class rows
|
417,965
mixed-class rows
|
$105,090 | -$24,651 | 05 Mar 2026 | |
| Leila Alland |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
45,909
|
$102,377 | — | 15 Sep 2023 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.15%
|
78,784
|
$98,480 | — | 31 Dec 2025 | |
| Deepika Jalota |
3/4/5
|
Chief Development Officer |
—
mixed-class rows
|
393,269
mixed-class rows
|
$95,761 | -$35,198 | 05 Mar 2026 | |
| Michael Carulli |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
313,848
mixed-class rows
|
$92,310 | -$30,077 | 05 Mar 2026 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
0.14%
|
73,211
|
$91,513 | — | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.12%
|
65,114
|
$81,392 | — | 31 Dec 2025 | |
| Seven Fleet Capital Management LP |
13F
|
Company |
0.12%
|
63,498
|
$79,373 | — | 31 Dec 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.12%
|
62,020
|
$78,000 | — | 31 Dec 2025 | |
| Rangeley Capital, LLC |
13F
|
Company |
0.09%
|
45,500
|
$56,875 | — | 31 Dec 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
0.07%
|
35,000
|
$43,750 | — | 31 Dec 2025 | |
| HSBC HOLDINGS PLC |
13F
|
Company |
0.06%
|
30,891
|
$39,386 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.05%
|
28,744
|
$35,930 | — | 31 Dec 2025 | |
| SIMPLEX TRADING, LLC |
13F
|
Company |
0.05%
|
27,862
|
$34,827 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.05%
|
27,536
|
$34,420 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for PMV Pharmaceuticals, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Michael Carulli | PMVP | Employee Stock Option (right to buy) | Award | 240,000 | 240,000 | 05 Mar 2026 | Direct | |||
| Robert Ticktin | PMVP | Employee Stock Option (right to buy) | Award | 319,270 | 319,270 | 05 Mar 2026 | Direct | |||
| Deepika Jalota | PMVP | Employee Stock Option (right to buy) | Award | 303,310 | 303,310 | 05 Mar 2026 | Direct | |||
| David Henry Mack | PMVP | Employee Stock Option (right to buy) | Award | 744,960 | 744,960 | 05 Mar 2026 | Direct | |||
| David Henry Mack | PMVP | Common Stock | Options Exercise | 95.7% | 220,643 | 451,109 | 27 Oct 2025 | Direct | ||
| David Henry Mack | PMVP | Employee Stock Option (right to buy) | Options Exercise | -100% | -220,643 | 0 | 27 Oct 2025 | Direct | ||
| Orbimed Advisors Llc | PMVP | Common Stock | Sale | -16.7% | $1,520,000 | $1.52 | -1,000,000 | 4,975,291 | 23 Oct 2025 | See Footnotes |
| Orbimed Advisors Llc | PMVP | Common Stock | Sale | -7.72% | $900,000 | $1.80 | -500,000 | 5,975,291 | 10 Sep 2025 | See Footnotes |
| Robert Ticktin | PMVP | Common Stock | Sale | -19% | $24,651 | $1.06 | -23,151 | 98,695 | 01 Jul 2025 | Direct |
| Deepika Jalota | PMVP | Common Stock | Sale | -26.9% | $35,198 | $1.06 | -33,065 | 89,959 | 01 Jul 2025 | Direct |
| Michael Carulli | PMVP | Common Stock | Sale | -32% | $30,077 | $1.06 | -28,249 | 60,146 | 01 Jul 2025 | Direct |
| David Henry Mack | PMVP | Common Stock | Sale | -9.82% | $62,179 | $1.06 | -58,411 | 536,133 | 01 Jul 2025 | Direct |
| Laurie Stelzer | PMVP | Stock Option (right to buy) | Award | 33,500 | 33,500 | 05 Jun 2025 | Direct | |||
| Arnold J. Levine | PMVP | Stock Option (right to buy) | Award | 33,500 | 33,500 | 05 Jun 2025 | Direct | |||
| Richard A. Heyman | PMVP | Stock Option (right to buy) | Award | 33,500 | 33,500 | 05 Jun 2025 | Direct | |||
| Carol Giltner Gallagher | PMVP | Stock Option (right to buy) | Gift | 33,500 | 33,500 | 05 Jun 2025 | See footnote | |||
| Carol Giltner Gallagher | PMVP | Stock Option (right to buy) | Gift | -100% | -33,500 | 0 | 05 Jun 2025 | Direct | ||
| Carol Giltner Gallagher | PMVP | Stock Option (right to buy) | Award | 33,500 | 33,500 | 05 Jun 2025 | Direct | |||
| Kirsten Flowers | PMVP | Stock Option (right to buy) | Award | 33,500 | 33,500 | 05 Jun 2025 | Direct | |||
| Charles M. Baum | PMVP | Stock Option (right to buy) | Award | 33,500 | 33,500 | 05 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.